Metopimazine Venipharm

Metopimazine, the active ingredient in Metopimazine Venipharm, is a phenothiazine derivative presented as an oral tablet for oral use. It acts as an antiemetic by blocking dopamine D2 receptors in the chemoreceptor trigger zone, helping to control nausea and vomiting in postoperative, chemotherapy, and other settings for patients.

GNH USA supplies Metopimazine Venipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Metopimazine is an antiemetic that works on the dopamine pathway to control nausea and vomiting.

- Nausea: reduces the sensation of nausea in various clinical situations. - Vomiting: limits the frequency and intensity of vomiting episodes. - Postoperative nausea and vomiting: helps prevent and treat nausea after surgery. - Chemotherapy‑induced nausea and vomiting: mitigates nausea associated with cancer treatment.

Metopimazine may cause a range of adverse reactions.

Common Side Effects: - Drowsiness: mild to moderate sedation. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: sensation of light‑headedness. - Blurred vision: temporary visual disturbance. - Weight gain: modest increase in appetite.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or dystonia. - Neuroleptic malignant syndrome: rare but life‑threatening hyperthermia and rigidity. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing cardiac disease.

Before prescribing Metopimazine, clinicians should consider several safety aspects.

- Assess renal function: adjust use in patients with severe impairment. - Monitor for extrapyramidal symptoms: watch for muscle rigidity or tremor. - Avoid use in patients with known hypersensitivity to phenothiazines. - Use caution in cardiovascular disease: risk of hypotension and arrhythmia. - Avoid concomitant use with other dopamine antagonists: increased CNS effects. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Metopimazine can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive central nervous system depression. - MAO inhibitors: risk of hypertensive crisis. - QT‑prolonging drugs (e.g., erythromycin): heightened potential for cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: increased anticholinergic burden. - CNS depressants (opioids, benzodiazepines): enhanced sedation. - CYP2D6 inhibitors (e.g., fluoxetine): possible alteration of Metopimazine plasma levels.